SI2827900T1 - Amorphous solid dispersion for use in the treatment of brain cancer - Google Patents

Amorphous solid dispersion for use in the treatment of brain cancer Download PDF

Info

Publication number
SI2827900T1
SI2827900T1 SI201331019T SI201331019T SI2827900T1 SI 2827900 T1 SI2827900 T1 SI 2827900T1 SI 201331019 T SI201331019 T SI 201331019T SI 201331019 T SI201331019 T SI 201331019T SI 2827900 T1 SI2827900 T1 SI 2827900T1
Authority
SI
Slovenia
Prior art keywords
solid dispersion
amorphous solid
use according
treatment
amorphous
Prior art date
Application number
SI201331019T
Other languages
English (en)
Slovenian (sl)
Inventor
Patrice A. Lee
Shannon L. Winski
Kevin Koch
Original Assignee
Array Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2827900(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma, Inc. filed Critical Array Biopharma, Inc.
Publication of SI2827900T1 publication Critical patent/SI2827900T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
SI201331019T 2012-03-23 2013-03-25 Amorphous solid dispersion for use in the treatment of brain cancer SI2827900T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23
PCT/US2013/033751 WO2013142875A1 (en) 2012-03-23 2013-03-25 Treatment of brain cancer
EP13714497.8A EP2827900B1 (en) 2012-03-23 2013-03-25 Amorphous solid dispersion for use in the treatment of brain cancer

Publications (1)

Publication Number Publication Date
SI2827900T1 true SI2827900T1 (en) 2018-06-29

Family

ID=48048296

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201331019T SI2827900T1 (en) 2012-03-23 2013-03-25 Amorphous solid dispersion for use in the treatment of brain cancer
SI201331844T SI3400943T1 (sl) 2012-03-23 2013-03-25 Spojine za uporabo pri zdravljenju možganskih metastaz pri bolniku z ErbB2+ rakom dojke

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331844T SI3400943T1 (sl) 2012-03-23 2013-03-25 Spojine za uporabo pri zdravljenju možganskih metastaz pri bolniku z ErbB2+ rakom dojke

Country Status (30)

Country Link
US (3) US20150110780A1 (cg-RX-API-DMAC7.html)
EP (4) EP3400943B1 (cg-RX-API-DMAC7.html)
JP (6) JP2015514075A (cg-RX-API-DMAC7.html)
KR (3) KR102160462B1 (cg-RX-API-DMAC7.html)
CN (2) CN109223791A (cg-RX-API-DMAC7.html)
AU (4) AU2013234921A1 (cg-RX-API-DMAC7.html)
CA (1) CA2867723C (cg-RX-API-DMAC7.html)
CL (1) CL2014002497A1 (cg-RX-API-DMAC7.html)
CO (1) CO7071139A2 (cg-RX-API-DMAC7.html)
CY (2) CY1120204T1 (cg-RX-API-DMAC7.html)
DK (2) DK2827900T3 (cg-RX-API-DMAC7.html)
ES (2) ES2673165T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180659T1 (cg-RX-API-DMAC7.html)
HU (2) HUE053156T2 (cg-RX-API-DMAC7.html)
IL (3) IL234627B (cg-RX-API-DMAC7.html)
LT (1) LT2827900T (cg-RX-API-DMAC7.html)
MX (1) MX354024B (cg-RX-API-DMAC7.html)
MY (2) MY174883A (cg-RX-API-DMAC7.html)
NZ (4) NZ724544A (cg-RX-API-DMAC7.html)
PH (2) PH12021550360A1 (cg-RX-API-DMAC7.html)
PL (2) PL2827900T3 (cg-RX-API-DMAC7.html)
PT (2) PT2827900T (cg-RX-API-DMAC7.html)
RS (1) RS57140B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018138976A (cg-RX-API-DMAC7.html)
SG (1) SG11201405954YA (cg-RX-API-DMAC7.html)
SI (2) SI2827900T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800251T1 (cg-RX-API-DMAC7.html)
TR (1) TR201808450T4 (cg-RX-API-DMAC7.html)
UA (1) UA122044C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013142875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
US20250387380A1 (en) * 2019-12-30 2025-12-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆(科克)有限公司 癌症治疗方法
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) * 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga

Also Published As

Publication number Publication date
KR20140139009A (ko) 2014-12-04
MY174883A (en) 2020-05-20
RS57140B1 (sr) 2018-07-31
IL269205A (en) 2019-11-28
PH12021550360A1 (en) 2023-04-03
EP3400943A1 (en) 2018-11-14
RU2672575C2 (ru) 2018-11-16
EP2827900A1 (en) 2015-01-28
US20190255051A1 (en) 2019-08-22
HK1206276A1 (en) 2016-01-08
AU2019203618A1 (en) 2019-06-13
PT2827900T (pt) 2018-06-14
DK2827900T3 (en) 2018-05-07
CA2867723A1 (en) 2013-09-26
EP4252855A3 (en) 2023-11-15
SI3400943T1 (sl) 2021-03-31
MX2014011437A (es) 2014-11-10
JP2015514075A (ja) 2015-05-18
LT2827900T (lt) 2018-05-10
CY1120204T1 (el) 2018-12-12
DK3400943T3 (da) 2021-02-08
AU2017272232C1 (en) 2019-08-15
CN104203279B (zh) 2018-10-30
JP2022190126A (ja) 2022-12-22
NZ630843A (en) 2017-01-27
CO7071139A2 (es) 2014-09-30
PT3400943T (pt) 2021-02-02
AU2017272232B2 (en) 2019-02-28
CA2867723C (en) 2022-11-08
KR20210131426A (ko) 2021-11-02
EP3400943B1 (en) 2020-12-02
HRP20180659T1 (hr) 2018-06-01
WO2013142875A1 (en) 2013-09-26
NZ724544A (en) 2018-05-25
MY202114A (en) 2024-04-04
PL2827900T3 (pl) 2018-08-31
CY1123837T1 (el) 2022-05-27
US20150110780A1 (en) 2015-04-23
KR102160462B1 (ko) 2020-09-28
AU2021261849A1 (en) 2021-12-02
NZ741615A (en) 2019-10-25
RU2018138976A3 (cg-RX-API-DMAC7.html) 2022-04-08
RU2018138976A (ru) 2018-12-06
ES2673165T3 (es) 2018-06-20
CL2014002497A1 (es) 2014-11-14
KR102317166B1 (ko) 2021-10-26
AU2017272232A1 (en) 2018-01-04
JP2024019526A (ja) 2024-02-09
KR102490961B1 (ko) 2023-01-19
NZ756264A (en) 2022-09-30
JP2017141302A (ja) 2017-08-17
RU2014142700A (ru) 2016-05-20
HUE053156T2 (hu) 2021-06-28
ES2855142T3 (es) 2021-09-23
IL261659A (en) 2018-10-31
US20230190749A1 (en) 2023-06-22
EP2827900B1 (en) 2018-03-21
SG11201405954YA (en) 2014-10-30
SMT201800251T1 (it) 2018-07-17
HUE037966T2 (hu) 2018-09-28
US11504370B2 (en) 2022-11-22
JP6898960B2 (ja) 2021-07-07
JP7404485B2 (ja) 2023-12-25
CN104203279A (zh) 2014-12-10
PL3400943T3 (pl) 2021-06-14
CN109223791A (zh) 2019-01-18
PH12014502032A1 (en) 2014-11-24
UA122044C2 (uk) 2020-09-10
AU2019203618B2 (en) 2021-08-05
KR20200115656A (ko) 2020-10-07
EP3842044A1 (en) 2021-06-30
MX354024B (es) 2018-02-08
JP2021178820A (ja) 2021-11-18
TR201808450T4 (tr) 2018-07-23
JP2019081792A (ja) 2019-05-30
AU2013234921A1 (en) 2014-10-02
IL269205B (en) 2020-06-30
EP4252855A2 (en) 2023-10-04
IL234627B (en) 2018-10-31

Similar Documents

Publication Publication Date Title
JP7404485B2 (ja) 脳癌の治療
JP7562296B2 (ja) がんの処置のための併用治療
JP2019081792A5 (cg-RX-API-DMAC7.html)
Yang et al. Indocyanine green-modified hollow mesoporous Prussian blue nanoparticles loading doxorubicin for fluorescence-guided tri-modal combination therapy of cancer
Kim et al. Past, present, and future of anticancer nanomedicine
ES2617983T3 (es) Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
FI3478286T3 (fi) Menetelmiä munasarjasyövän hoitamiseksi
JP2014512356A5 (cg-RX-API-DMAC7.html)
JP2015503613A5 (cg-RX-API-DMAC7.html)
BR112012013951A2 (pt) formulação farmacêutica de nanopartículas e respectivos métodos de preparação e usos
HRP20161712T1 (hr) Sol fotosenzibilizirajućeg agensa za uporabu u fotokemijskoj internalizaciji
JP2015536996A5 (cg-RX-API-DMAC7.html)
US20130266508A1 (en) Thermosensitive hydrogel for coating radioisotope and chemotherapeutic agent to treat cancer and method for preparing the same
JP2019513134A5 (cg-RX-API-DMAC7.html)
Dong et al. Novel combination treatment for melanoma: FLASH radiotherapy and immunotherapy delivered by a radiopaque and radiation responsive hydrogel
Wang et al. MIL-100 (Fe)-based Co-delivery platform as cascade synergistic chemotherapy and immunotherapy agents for colorectal cancer via the cGAS-STING pathway
JP2021528368A5 (cg-RX-API-DMAC7.html)
JP2014510047A5 (cg-RX-API-DMAC7.html)
JP7372740B2 (ja) 細胞生存性及び/又は細胞増殖を低減するための薬物の組み合わせ
KR20250044436A (ko) Cdk7 억제제와 기타 항암 치료제의 병용 치료
XU et al. Chemoradiation effect of combined preoperative intensity-modulated radiotherapy with oral capecitabine in patients with locally advanced mid-low rectal cancer using a simultaneous integrated boost of tomotherapy
RU2012153433A (ru) Препарат для фотодинамической терапии и способ фотодинамической терапии рака с его использованием
RU2021110680A (ru) Комбинированная терапия, включающая соединение ацилтиомочевины и абиратерон
Okamoto et al. Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma.